生物股份子公司取得新兽药注册证书

Core Viewpoint - The approval of the inactivated vaccine for porcine parvovirus by the Ministry of Agriculture and Rural Affairs represents a significant achievement for the company, highlighting its commitment to research and development innovation in the animal vaccine sector [1] Group 1: Product Development - The newly approved vaccine, developed by the company's subsidiary Yangzhou Youbang Biological Pharmaceutical Co., Ltd. and Jin Yu Bao Ling Biological Pharmaceutical Co., Ltd., is classified as a new veterinary drug [1] - This product enhances the company's portfolio of swine vaccines, reflecting years of accumulated expertise in the field [1] Group 2: Market Position and Strategy - The successful approval of the vaccine strengthens the company's position in the animal vaccine industry and supports its ability to provide comprehensive disease prevention solutions to livestock customers [1] - The company aims to meet diverse market demands through its extensive product offerings, which contribute positively to its research capabilities, market competitiveness, and sustainable development [1]